Cho Esther 4
4 · Keros Therapeutics, Inc. · Filed Feb 20, 2026
Research Summary
AI-generated summary of this filing
Keros Therapeutics (KROS) SVP Esther Cho Sells 4,745 Shares
What Happened
Esther Cho, SVP and General Counsel of Keros Therapeutics (KROS), disposed of 4,745 shares on February 18, 2026 in a sale that generated approximately $77,581 in proceeds. The sale was a sell-to-cover related to the vesting of restricted stock units, meaning shares were sold to satisfy tax withholding rather than an open-market discretionary divestment.
Key Details
- Transaction date: 2026-02-18 (reported on Form 4 filed 2026-02-20 — timely filing).
- Transaction type: Sale (code S) to cover tax withholding for vested RSUs (automatic, not at Cho’s discretion) — footnote F1.
- Shares sold: 4,745; weighted average price: $16.35; total proceeds: $77,581. Price range across multiple trades: $16.05–$16.65 (footnote F2).
- Other note: Filing indicates 500 shares were acquired under the issuer’s 2020 Employee Stock Purchase Plan (footnote F3).
- Shares owned after the transaction: not stated in the provided excerpt of the filing.
Context
Sell-to-cover transactions are routine tax-related sales tied to equity awards vesting and are generally not read as a strong signal of management sentiment. This was not an exercise-and-sell or a discretionary open-market sell plan; the filing states the sales were automatic to satisfy tax withholding obligations.
Insider Transaction Report
- Sale
Common Stock
[F1][F2][F3]2026-02-18$16.35/sh−4,745$77,581→ 39,755 total
Footnotes (3)
- [F1]The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.05 to $16.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Includes an aggregate of 500 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan.